Biohaven Pharmaceutical Holding Company Ltd.
NYSE:BHVN
50.88 (USD) • At close November 1, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2017 | |
|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 462.509 | 0 | 0 | 0 |
| Cost of Revenue
| 3.369 | 1.386 | 91.664 | 0.072 | 0 | 0 |
| Gross Profit
| -3.369 | -1.386 | 370.845 | -0.072 | 0 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0.802 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 373.281 | 437.072 | 181.486 | 98.46 | 344.673 | 0 |
| General & Administrative Expenses
| 56.896 | 130.86 | 37.414 | 16.046 | 134.449 | 0 |
| Selling & Marketing Expenses
| 5.874 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 62.77 | 130.86 | 37.414 | 16.046 | 134.449 | 0 |
| Other Expenses
| 0 | -1.909 | 1.209 | 0 | 0 | 0 |
| Operating Expenses
| 436.051 | 567.932 | 218.9 | 114.506 | 479.122 | 0 |
| Operating Income
| -436.051 | -567.932 | -218.9 | -114.506 | -479.122 | 0 |
| Operating Income Ratio
| 0 | 0 | -0.473 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 26.5 | -1.909 | 6.47 | -4.162 | -49.264 | 0 |
| Income Before Tax
| -409.551 | -569.841 | -212.43 | -118.668 | -528.386 | 0 |
| Income Before Tax Ratio
| 0 | 0 | -0.459 | 0 | 0 | 0 |
| Income Tax Expense
| 1.383 | 0.438 | 1.366 | -0.134 | 0.419 | 0 |
| Net Income
| -408.168 | -570.279 | -213.796 | -118.668 | -528.805 | 0 |
| Net Income Ratio
| 0 | 0 | -0.462 | 0 | 0 | 0 |
| EPS
| -5.73 | -12.75 | -5.97 | -3.31 | -10.91 | 0 |
| EPS Diluted
| -5.73 | -12.75 | -5.97 | -3.31 | -10.91 | 0 |
| EBITDA
| -429.139 | -566.546 | -217.507 | -114.434 | -479.122 | 0 |
| EBITDA Ratio
| 0 | 0 | -0.47 | 0 | 0 | 0 |